Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review [PDF]
Journal of International Medical Research, 2019 Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti ...
Horace Massa +5 more
doaj +2 more sources
Recurrent Diabetic Macular Edema: What to Do [PDF]
Case Reports in Ophthalmology, 2017 Diabetic macular edema (DME) is a leading cause of blindness in the working population. Herein, we report the case of a patient with recurrent DME for about 6 years, uncontrolled by several medical and surgical treatments, that was successfully treated ...
Rita Santos Gonçalves +2 more
doaj +3 more sources
Efficacy and Safety of Fluocinolone Acetonide Implant in Diabetic Macular Edema: Practical Guidelines from Reference Center [PDF]
PharmaceuticsDiabetic macular edema (DME) is a common complication of diabetic retinopathy. Treatment with intravitreal injections is effective in most cases but is associated with a high therapeutic burden for patients. This implies the need for long-term treatments,
Lucas Sejournet +6 more
doaj +2 more sources
Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review [PDF]
Pharmaceutics, 2021 To assess real-world outcomes of fluocinolone acetonide (FAc) implant in treating diabetic macular edema (DME), a systematic literature review was conducted on PubMed in order to identify publications assessing the efficacy and safety of the FAc implant ...
Laurent Kodjikian +6 more
doaj +2 more sources
Treatment of refractory diabetic macular edema with a fluocinolone acetonide implant in vitrectomized and non-vitrectomized eyes [PDF]
International Journal of Ophthalmology, 2018 AIM: To report real-life data on the use of an intravitreal fluocinolone acetonide implant in the treatment of refractory diabetic macular edema (DME) in pars plana vitrectomized (PPV) and non-PPV eyes.
Alberto La Mantia +4 more
doaj +2 more sources
Clinical-decision criteria to identify recurrent diabetic macular edema patients suitable for fluocinolone acetonide implant therapy (Iluvien®) and follow-up considerations/ recommendations [PDF]
Clin Ophthalmol, 2020 Current management of diabetic macular edema (DME) predominantly involves treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors (anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting ...
Abraldes, M. +10 more
core +4 more sources
Intrascleral Tunnel Clamping of Fluocinolone Acetonide Implant: A Novel Scleral Fixation Technique [PDF]
PharmaceuticalsPurpose: This retrospective observational study evaluates the efficacy and safety of a novel scleral fixation technique of the fluocinolone acetonide (FAc) implant in four consecutive patients with post-surgical macular edema (PSME).
Lucas Sejournet +5 more
doaj +2 more sources
Ahmed glaucoma valve in uveitic patients with fluocinolone acetonide implant-induced glaucoma: 3-year follow-up [PDF]
Clinical Ophthalmology, 2018 Buraa Kubaisi,1,2 Arash Maleki,1,2 Aseef Ahmed,1,2 Neel Lamba,1,2 Haitham Sahawneh,1,2 Andrew Stephenson,1,2 Alyssa Montieth,1,2 Shobha Topgi,3 C Stephen Foster1,2,4 1Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA; 2Ocular ...
Kubaisi B +8 more
doaj +2 more sources
The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema [PDF]
International Medical Case Reports Journal, 2018 P Singh,1 A Chedid,1 SK Deuchler,1 T Kohnen,2 M Müller,2 FH Koch1 1Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany; 2Ophthalmology University Eye Hospital, Frankfurt am Main, Germany Purpose: There are little or no ...
Singh P +5 more
doaj +2 more sources
Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
Drug Design, Development and Therapy, 2013 Wyatt B Messenger, Robert M Beardsle, Christina J FlaxelCasey Eye Institute, Oregon Health and Science University, Portland, OR, USAAbstract: Diabetic macular edema (DME) remains one of the leading causes of moderate to severe vision loss. Although laser
Messenger WB, Beardsley RM, Flaxel CJ
doaj +4 more sources